Nektar Therapeutics Q3 2024 Earnings Preview
Nektar Therapeutics (NASDAQ:NKTR) is scheduled to announce Q3 earnings results on Thursday, November 7th, after market close. The consensus EPS Estimate is -$0.21 (-10.5% Y/Y) and the consensus Revenue Estimate is $18.
Nektar: Q3 Earnings Snapshot
SAN FRANCISCO — SAN FRANCISCO — Nektar Therapeutics (NKTR) on Thursday reported a loss of $37.1 million in its third quarter. On a per-share basis, the San Francisco-based company said it had a loss of 18 cents. The results beat Wall Street expectations.
Block: Q3 Earnings Snapshot
The average estimate of eight analysts surveyed by Zacks Investment Research was also for earnings of 88 cents per share. The mobile payments services provider posted revenue of $5.98 billion in the period,
Qurate Retail: Q3 Earnings Snapshot
Qurate Retail Group, Inc. (QRTEA) on Thursday reported a loss of $23 million in its third quarter. On a per-share basis, the Englewood, Colorado-based company said it had a loss of 6 cents. The online commerce holding company posted revenue of $2.
Chatham Lodging: Q3 Earnings Snapshot
Chatham Lodging Trust (CLDT) on Thursday reported a key measure of profitability in its third quarter. The results met Wall Street expectations. The West Palm Beach, Florida-based real estate investment trust said it had funds from operations of $17.
DraftKings: Q3 Earnings Snapshot
DraftKings Inc. (DKNG) on Thursday reported a loss
FiercePharma12h
Biologics CDMO Avid Bioservices to go private with $1.1B sale to Ampersand, GHO Capital
Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...
Nektar presents late-breaking results from Phase 2 Study of NKTR-255
Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...
Zacks.com on MSN4h
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.19 per share a year ago. These figures ...
FiercePharma3d
Nektar pads wallet with $90M manufacturing plant sale to Ampersand
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...
bovnews2d
Piper Sandler Issues Overweight Rating for Nektar Therapeutics (NKTR) Stock
On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 ...
BioPharma Dive1d
Moderna said to shuffle sales leadership; Vertex records first Casgevy sale
Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...
Nektar Therapeutics to Participate in Upcoming Investor Conferences
Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: ...
Nektar To Sell Manufacturing Facility In Alabama, Reagent Supply Business To Ampersand
(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...
MM&M13h
Rx Rundown: Avid Biosciences, Novo Nordisk, Zealand Pharma and more
Nektar Therapeutics is selling its Huntsville, Alabama, manufacturing plant and reagent supply business to private equity firm Ampersand Capital Partners for $90 million. Ascendis Pharma and Novo ...